Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial von Schmoll, Hans-Joachim, Mann, Julia, Meinert, Fabian, Garlipp, Benjamin, Borchert, Kersten, Vogel, Arndt, Goekkurt, Eray, Kaiser, Ulrich, Hoeffkes, Heinz-Gert, Rüssel, Jörn, Kanzler, Stephan, Edelmann, Thomas, Forstbauer, Helmut, Göhler, Thomas, Hannig, Carla, Hildebrandt, Bert, Roll, Carsten, Bokemeyer, Carsten, Steighardt, Jörg, Cygon, Franziska, Ibach, Stefan, Stein, Alexander, Tintelnot, Joseph

Volltext

Phase II-study of sequential high-dose-chemotherapy with paclitaxel, ifosfamide, carboplatin, etoposide( P-ICE) in patients with relapsed or refractory germ cell tumors (GCT) von Kegel, Thomas, Cygon, Franziska, Meinert, Fabian Maximilian, Hammad, Khaled, Steinbach, Frank, Seseke, Florian, Schmoll, Hans-Joachim

Volltext

Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO von Schmoll, Hans-Joachim, Rüssel, Jörn, Reichardt, Peter, Lindner, Lars, Kopp, Hans-Georg, Stein, Alexander, Cygon, Franziska, Heissner, Klaus

Volltext

FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis von Schmoll, Hans-Joachim, Garlipp, Benjamin, Junghanß, Christian, Leithäuser, Malte, Vogel, Arndt, Schaefers, Michael, Kaiser, Ulrich, Hoeffkes, Heinz-Gert, Florschütz, Axel, Rüssel, Jörn, Kanzler, Stephan, Edelmann, Thomas, Forstbauer, Helmut, Göhler, Thomas, Hannig, Carla, Hildebrandt, Bert, Steighardt, Jörg, Cygon, Franziska, Meinert, Fabian, Stein, Alexander

Volltext

“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial... von Schmoll, Hans-Joachim, Meinert, Fabian Maximilian, Cygon, Franziska, Garlipp, Benjamin, Junghanss, Christian, Leithäuser, Malte, Vogel, Arndt, Schaefers, Michael, Kaiser, Ulrich, Hoeffkes, Heinz-Gert, Florschütz, Axel, Rüssel, Jörn, Kanzler, Stephan, Edelmann, Thomas, Forstbauer, Helmut, Goehler, Thomas, Hannig, Carla, Hildebrandt, Bert, Steighardt, Jörg, Stein, Alexander

Volltext

CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209) von Schmoll, Hans-Joachim, Garlipp, Benjamin, Junghanss, Christian, Leithaeuser, Malte, Vogel, Arndt, Schaefers, Michael, Kaiser, Ulrich, Hoeffkes, Heinz-Gert, Florschütz, Axel, Rüssel, Jörn, Kanzler, Stephan, Edelmann, Thomas, Forstbauer, Helmut, Goehler, Thomas, Hannig, Carla, Hildebrandt, Bert, Steighardt, Jörg, Meinert, Fabian Maximilian, Cygon, Franziska, Stein, Alexander

Volltext

LBA-007FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (AIO) "CHARTA": Final results and multivariate prognostic factor analysis von Schmoll, Hans-Joachim, Garlipp, Benjamin, Junghanß, Christian, Leithäuser, Malte, Vogel, Arndt, Schaefers, Michael, Kaiser, Ulrich, Hoeffkes, Heinz-Gert, Florschütz, Axel, Rüssel, Jörn, Kanzler, Stephan, Edelmann, Thomas, Forstbauer, Helmut, Göhler, Thomas, Hannig, Carla, Hildebrandt, Bert, Steighardt, Jörg, Cygon, Franziska, Meinert, Fabian, Stein, Alexander

Volltext

Creld2 function during unfolded protein response is essential for liver metabolism homeostasis von Kern, Paul, Balzer, Nora R., Blank, Nelli, Cygon, Cornelia, Wunderling, Klaus, Bender, Franziska, Frolov, Alex, Sowa, Jan‐Peter, Bonaguro, Lorenzo, Ulas, Thomas, Homrich, Mirka, Kiermaier, Eva, Thiele, Christoph, Schultze, Joachim L., Canbay, Ali, Bauer, Reinhard, Mass, Elvira

Volltext